SARS CoV-2 Spike Glycoprotein UK variant Blocking Peptide for STJ506293 peptide (UK variant) (STJ506296)
SPECIFICATIONS
General Information
| Short Description | SARS CoV-2 Spike Glycoprotein UK variant Blocking Peptide for STJ506293 is synthetically produced from the 650-800 sequence about the UK variant and is suitable for use in western blot applications. |
| Applications | Immunodepletion/Immunocompetition |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Formulation | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Target Information
| Immunogen Region | 650-800 |
| Specificity | This blocking peptide is recommended for use in combination with SARS CoV-2 Spike Glycoprotein UK variant antibody, STJ506293 |